Tumor budding is a well-established independent prognostic factor in colorectal cancer but a standardized method for its assessment has been lacking. The primary aim of the International Tumor Budding Consensus Conference (ITBCC) was to reach agreement on an international, evidence-based standardized scoring system for tumor budding in colorectal cancer. The ITBCC included nine sessions with presentations, a pre-meeting survey and an e-book covering the key publications on tumor budding in colorectal cancer. The 'Grading of Recommendation Assessment, Development and Evaluation' method was used to determine the strength of recommendations and quality of evidence. The following 10 statements achieved consensus: tumor budding is defined as a single tumor cell or a cell cluster consisting of four tumor cells or less (22/22, 100%). Tumor budding is an independent predictor of lymph node metastases in pT1 colorectal cancer (23/23, 100%). Tumor budding is an independent predictor of survival in stage II colorectal cancer (23/23, 100%). Tumor budding should be taken into account along with other clinicopathological features in a multidisciplinary setting (23/23, 100%). Tumor budding is counted on H&E (19/22, 86%). Intratumoral budding exists in colorectal cancer and has been shown to be related to lymph node metastasis (22/22, 100%). Tumor budding is assessed in one hotspot (in a field measuring 0.785 mm) at the invasive front (22/22, 100%). A three-tier system should be used along with the budding count in order to facilitate risk stratification in colorectal cancer (23/23, 100%). Tumor budding and tumor grade are not the same (23/23, 100%). Tumor budding should be included in guidelines/protocols for colorectal cancer reporting (23/23, 100%). Members of the ITBCC were able to reach strong consensus on a single international, evidence-based method for tumor budding assessment and reporting. It is proposed that this method be incorporated into colorectal cancer guidelines/protocols and staging systems.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/modpathol.2017.46 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term outcomes of endoscopic submucosal dissection for T1b colorectal cancer.
J Cancer Res Ther
December 2024
Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, P. R. China.
Background: Endoscopic submucosal dissection (ESD) is a standardized procedure for intramucosal and slightly invasive submucosal colorectal cancers (CRC). However, the role of ESD for T1b (depth of submucosal invasion: ≥1,000 μm) CRC remains unclear. This study aimed to investigate the long-term efficacy and safety of ESD for T1b CRC.
View Article and Find Full Text PDFColorectal Cancer: A Brief and Simplified Analysis of a Complex Disease.
Medicina (Kaunas)
December 2024
Department of Medical Genetics, Faculty of Pharmacy, Medical University, 5800 Pleven, Bulgaria.
This study examined factors influencing the onset and progression of colorectal tumors, including patients' epidemiological data, tumor location (right-sided, left-sided, and rectal), histomorphology, perineural or intraneural invasion, lymph node status, immune reactions, mismatch repair (MMR) status, and commonly observed mutations. Our primary goal was to evaluate their predictive and prognostic value and interactions. We analyzed a retrospective cohort of 100 patients with colorectal adenocarcinoma diagnosed between 2020 and 2023, using formalin-fixed paraffin-embedded (FFPE) tumor blocks.
View Article and Find Full Text PDFLong-term prognostic outcomes in high-risk T1 colorectal cancer: A multicentre retrospective comparison of surgery versus observation postendoscopic treatment.
Colorectal Dis
January 2025
Department of Surgery, Yokohama City University, Yokohama, Kanagawa, Japan.
Aim: The risk of lymph node metastasis after endoscopic resection of high-risk T1 colorectal cancer prompts additional resection. However, age and comorbidities are considered in decision-making and some surgeons opt for observation. We compared the long-term outcomes of these approaches with the aim of clarifying the need for additional resection.
View Article and Find Full Text PDFComparison of the prognosis and lymph node metastasis between no tumor budding and low-grade tumor budding in T1 and T2 colorectal cancer.
Sci Rep
January 2025
Department of Pathology, Ulsan University Hospital, University of Ulsan College of Medicine, 25 Daehakbyeong-Ro, Dong-Gu, Ulsan, 44033, South Korea.
Tumor budding is a significant prognostic factor in colorectal cancer (CRC) management and is graded as follows: 0-4 buds as low, 5-9 buds as intermediate, and > 10 buds as high. However, the specific prognostic difference between cases with 0 buds (BD0) and those with 1-4 buds (BD1) is not well established owing to a lack of comparative studies. This study aimed to examine and compare the rate of lymph node (LN) metastasis and prognosis by distinguishing between BD0 and BD1 within the low-grade category (0-4 buds) of tumor budding in submucosa (T1) and muscularis propria (T2) CRC.
View Article and Find Full Text PDFRisk Factors Associated With Lymph Node Metastasis and Recurrence in Surgical Cases of pT1 Colorectal Cancer.
Cureus
December 2024
Surgery, Shiga General Hospital, Moriyama, JPN.
Objective This study aims to investigate the risk factors for lymph node metastasis (LNM) and postoperative recurrence in patients undergoing surgery for pT1 colorectal cancer (pT1-CRC). Materials and methods We retrospectively analyzed 150 patients who underwent bowel resection with lymph node dissection for pT1-CRC at our department between September 2011 and December 2021. Univariate and multivariate analyses were performed to examine the effects of sex, depth of tumor invasion, venous invasion, lymphatic invasion, tumor budding (BD), and histological type on LNM and recurrence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!